An Open Label, Partially Randomized, Four-period Study in Healthy Male Subjects to Investigate the Bioavailability and Pharmacokinetics of a Single Dose of AZD7594 When Administered Intravenously, Orally and Inhaled Via Two Different Dry Powder Inhalers (DPI) and a Pressurized Metered-dose Inhaler (pMDI)

Trial Profile

An Open Label, Partially Randomized, Four-period Study in Healthy Male Subjects to Investigate the Bioavailability and Pharmacokinetics of a Single Dose of AZD7594 When Administered Intravenously, Orally and Inhaled Via Two Different Dry Powder Inhalers (DPI) and a Pressurized Metered-dose Inhaler (pMDI)

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs AZD 7594 (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 15 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.
    • 15 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top